Study supports Innogenetics' tests for AD (Alzheimer's disease)
This article was originally published in Clinica
Executive Summary
The combination of two cerebrospinal fluid (CSF)-based tests for Alzheimer's disease (AD) can confirm or rule out the disease with an accuracy of more than 90%, according to a Swedish study. The researchers say that the tests, which detect levels of beta-amyloid-42 peptide and tau protein respectively, should be included in the clinical work-up of patients with cognitive impairment, especially to differentiate early AD from normal ageing and psychiatric disorders.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.